Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT00543387 2024-06-05

MK-5108-001

Phase 1 Completed

35 enrolled 15 charts

Tumor-Agnostic

Neoplasms

NCT01920061 2022-09-13

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Phase 1 Completed

110 enrolled 80 charts

Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1 Completed

122 enrolled

Tumor-Agnostic

Neoplasms

NCT03057366 2019-11-18

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Phase 1 Completed

8 enrolled 26 charts

Tumor-Agnostic

Neoplasms

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT01868022 2019-08-19

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Phase 1 Completed

65 enrolled 32 charts

Tumor-Agnostic

Neoplasms

NCT00704821 2019-05-10

PTC299 for Treatment of Advanced Cancer

Phase 1 Terminated

76 enrolled

Tumor-Agnostic

Neoplasms

NCT00148902 2017-12-06

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Phase 1 Completed

52 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT00201812 2017-12-06

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

27 enrolled

Tumor-Agnostic

Neoplasms

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1 Completed

74 enrolled

Tumor-Agnostic

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

169 enrolled

Tumor-Agnostic

Neoplasms

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Phase 1 Completed

29 enrolled

Tumor-Agnostic

Neoplasms

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

104 enrolled

Tumor-Agnostic

Neoplasms

NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

172 enrolled 13 charts

Lymphoid

Lymphoma, Neoplasms

NCT00487786 2016-01-18

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Phase 1 Completed

64 enrolled

Tumor-Agnostic

Neoplasms

NCT01685489 2015-10-27

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

Phase 1 Withdrawn

Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01611961 2014-09-30

Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients

Phase 1 Unknown

35 enrolled

Tumor-Agnostic

Neoplasms

NCT02171676 2014-06-24

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

40 enrolled

Tumor-Agnostic

Neoplasms

NCT02171741 2014-06-24

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

31 enrolled

Tumor-Agnostic

Neoplasms

NCT00183742 2014-05-22

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Phase 1 Completed

35 enrolled

Tumor-Agnostic

Carcinoma, Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

Phase 1 Completed

39 enrolled

Tumor-Agnostic

Neoplasms

NCT00808418 2014-02-03

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

Phase 1 Completed

34 enrolled

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00545246 2013-10-16

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Phase 1 Completed

12 enrolled

Tumor-Agnostic

Neoplasms

NCT01095302 2013-10-16

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Phase 1 Completed

11 enrolled

Tumor-Agnostic

Neoplasms

NCT00322400 2013-07-31

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

Phase 1 Completed

46 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01604863 2012-11-01

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Phase 1 Suspended

54 enrolled

GenitourinaryOther solid neoplasmThoracic

Lung Neoplasms, Mesothelioma, Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT01204996 2012-05-30

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Phase 1 Completed

53 enrolled

Tumor-Agnostic

Neoplasms

NCT00454649 2012-04-04

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Phase 1 Completed

102 enrolled 48 charts

Tumor-Agnostic

Neoplasms

NCT00125411 2012-03-26

Study of Satraplatin (JM-216) in Combination With Docetaxel

Phase 1 Terminated

28 enrolled

Tumor-Agnostic

Neoplasms

NCT00606814 2012-03-06

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

Phase 1 Completed

60 enrolled

Tumor-Agnostic

Neoplasms

NCT01148615 2012-01-13

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

Phase 1 Completed

20 enrolled

Tumor-Agnostic

Neoplasms

NCT00390676 2010-12-28

A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

Phase 1 Completed

Tumor-Agnostic

Neoplasms

NCT00049296 2010-06-11

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Phase 1 Completed

26 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckLymphoidOther hematologic neoplasmPlasma cellSarcomaThoracic

AIDS-related Kaposi sarcoma, Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Appendiceal Neoplasms, Astrocytoma, Bile Duct Neoplasms, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Chondrosarcoma, Colonic Neoplasms, Craniopharyngioma, Ependymoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glioblastoma, Glioma, Carcinoma, Hepatocellular, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Meningioma, Multiple Myeloma, Neoplasms, Neuroblastoma, Oligodendroglioma, Pancreatic Neoplasms, Pinealoma, Rectal Neoplasms, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Kaposi, Osteosarcoma, Stomach Neoplasms, Urethral Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive, Esthesioneuroblastoma, Olfactory, Glioma, Subependymal, Gliosarcoma, Lymphoma, B-Cell, Marginal Zone, Breast Neoplasms, Male, Lymphoma, Mantle-Cell, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Small Cell Lung Carcinoma

NCT00193570 2009-01-23

Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors

Phase 1 Completed

20 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

A Study of ASP3082 in Adults With Advanced Solid Tumors

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

IVY

MK-5108-001

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

MK-2206-003

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

PTC299 for Treatment of Advanced Cancer

Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Study of ABT-700 in Subjects With Advanced Solid Tumors

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase I Study of LB-100 With Docetaxel in Solid Tumors

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer

Docetaxel Lipid Microsphere (DT-LM) for Injection in Chemotherapy Patients

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors

Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)

Phase I Trial of Docetaxel With Perifosine

A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer

A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Study of Satraplatin (JM-216) in Combination With Docetaxel

Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors

A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors

A Study of ADH 1 in Combination With Carboplatin, or Docetaxel or Capecitabine

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors